Announcement PDF ASX Announcement Race releases 2020 AGM presentation video  CEO/MD, Phil Lynch and CSO/ED, Dr Daniel Tillett deliver Race’s AGM presentation  Overview of the Three Pillar strategy for the development of Bisantrene 16 December 2020 – Race Oncology Limited (Race or the Company) (ASX: RAC) is pleased to release an extended version of the presentation from our 2020 Annual General Meeting (AGM) as stated (ASX Announcement: 30 November 2020). Race's Managing Director and CEO, Mr Phil Lynch commented, “At the time we released our updated Three Pillar strategy at our AGM, we committed to making available a video presentation to those shareholders who could not attend our virtual meeting. We outline the strategic development of Bisantrene, both at a low dose for the treatment of cancers where FTO is overexpressed, and at a high dose as a heart friendlier chemotherapeutic in a range of areas, including breast cancer and AML.” Investors are invited to access the video via the following link: https://www.raceoncology.com/race-oncologys-2020-agm/. -ENDSAbout Race Oncology (ASX: RAC) Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrene. Bisantrene is a potent inhibitor of the Fat mass and obesity associated (FTO) protein. Over-expression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Bisantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Bisantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas. Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar’ strategy for the clinical development of Bisantrene. See more at www.raceoncology.com. Race Oncology Ltd ABN 61 149 318 749 Registered office: L36, 1 Macquarie Place, Sydney NSW 2000 www.raceoncology.com Release authorised by: Media contact: Phil Lynch, CEO/MD on behalf Jane Lowe of the Race Board of Directors +61 411 117 774 phillip.lynch@raceoncology.com jane.lowe@irdepartment.com.au Race Oncology Ltd ABN 61 149 318 749 Registered office: L36, 1 Macquarie Place, Sydney NSW 2000 www.raceoncology.com